February 7, 2018 / 12:14 PM / 6 months ago

BRIEF-Verastem Submits Marketing Application To FDA For Duvelisib

Feb 7 (Reuters) - Verastem Inc:

* VERASTEM SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR DUVELISIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA AND FOLLICULAR LYMPHOMA

* VERASTEM INC - LOOK FORWARD TO WORKING WITH FDA DURING REVIEW PROCESS AND TO POTENTIAL U.S. APPROVAL DECISION FOR DUVELISIB IN EARLY 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below